Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

10.1007/s00280-013-2132-y

Saved in:

書目詳細資料
Main Authors:	Sudo, M., Chin, T.M., Mori, S., Doan, N.B., Said, J.W., Akashi, M., Koeffler, H.P.
其他作者:	CANCER SCIENCE INSTITUTE OF SINGAPORE
格式:	Article
出版:	2014
主題:	17-DMAG Belinostat Combination chemotherapy EGFR Non-small cell lung cancer (NSCLC) Tyrosine kinase inhibitor (TKI)
在線閱讀:	http://scholarbank.nus.edu.sg/handle/10635/116416
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	National University of Singapore

相似書籍

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
由: Salto-Tellez, M., et al.
出版: (2014)

TARGETING THE PIK3 PATHWAY IN NON-SMALL CELL LUNG CANCER
由: DANIEL TAN SHAO WENG
出版: (2017)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
由: Chin, T.-M., et al.
出版: (2021)

Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with egfr tki and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells
由: Dyrstad, Sissel E., et al.
出版: (2022)

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
由: Lee, S.-C., et al.
出版: (2012)

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy
由: Soo, R.A., et al.
出版: (2014)

CAV1 - GLUT3 signaling is important for cellular energy and can be targeted by Atorvastatin in Non-Small Cell Lung Cancer
由: Ali, A., et al.
出版: (2022)

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases
由: Pang, B., et al.
出版: (2014)

Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer
由: Song, L., et al.
出版: (2021)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
由: Park, Keunchil, et al.
出版: (2022)

REGULATION OF AMPK ACTIVATION AND ITS ROLE IN CELL DEATH INDUCED BY GLUCOSE STARVATION IN LKB1-MUTANT HUMAN LUNG CANCER CELLS
由: REN YI
出版: (2019)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
由: Assiddiq, B.F., et al.
出版: (2014)

A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients
由: Wang, L.-Z., et al.
出版: (2014)

CLINICAL AND FUNCTIONAL SIGNIFICANCE OF CD151 IN WILDTYPE EGRF NSCLC
由: WONG HUEE PING AMANDA
出版: (2020)

EXPLORING RECEPTOR TYROSINE KINASES IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
由: BHAVE SAYALI SHRIVARDHAN
出版: (2023)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
由: Ma, Jun, et al.
出版: (2024)

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
由: Sudo M., et al.
出版: (2020)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
由: Yeo, W.-L., et al.
出版: (2011)

EGF-induced tyrosine phosphorylation of Endofin is dependent on PI3K activity and proper localization to endosomes
由: Toy, W., et al.
出版: (2014)

Endofin is a novel component in EGR/EGFR oncogenic signaling
由: TOY WEIYI
出版: (2011)

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
由: Chang, Gee-Chen, et al.
出版: (2022)

EXPLORING TARGETED AND NON-TARGETED APPROACHES IN THE DEVELOPMENT OF ANTI-FIBROTIC THERAPY FOR LIVER FIBROSIS
由: SOH KAR LING CARRIE
出版: (2017)

Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase
由: Meyer, T., et al.
出版: (2016)

Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses
由: Ninnutt Moonrin, et al.
出版: (2015)

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy
由: Limviphuvadh, Vachiranee, et al.
出版: (2018)

RESISTANCE TO FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA: MOLECULAR MECHANISMS AND RESENSITIZING STRATEGIES
由: Zhou, J, et al.
出版: (2019)

The study on association of focal adhesion kinase in HGF-mediated cell proliferation and invasion in human cholangiocarcinoma cell line, HuCCa-1
由: Urai Pongchairerk
出版: (2023)

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
由: Tan, Eng-Huat, et al.
出版: (2022)

MOLECULAR RISK STRATIFICATION OF EARLY-STAGE RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED NON-SMALL CELL LUNG CANCER
由: SAW PEI LI, STEPHANIE
出版: (2025)

Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease
由: Bhave, Sayali, et al.
出版: (2022)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
由: Ku, G.Y., et al.
出版: (2016)

Symptom clusters and their influences on the functional status in advanced lung cancer patients receiving chemotherapy
由: Thidarat Khamboon
出版: (2023)

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
由: Ho, H.K., et al.
出版: (2016)

Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure
由: Saw, Stephanie PL, et al.
出版: (2024)

THE ROLE OF RTKS IN CELL RIGIDITY SENSING REGULATION
由: YANG BO
出版: (2017)

RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
由: Omar, M.F.M., et al.
出版: (2014)

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
由: Schuler, M, et al.
出版: (2024)

Self-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapy
由: Lim, Wei Qi, et al.
出版: (2021)

Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings
由: Dettmer, M., et al.
出版: (2016)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
由: Ma, L, et al.
出版: (2020)